Immunocore
Immunocore's revenue rose 28.9% to $400 million in fiscal 2025. Its operating margin was −11.3%, up from −22.7% a year earlier. Free cash flow was −$15 million, against $21 million a year earlier. The diluted share count rose 0.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Immunocore lost money in fiscal 2025: a net loss of $36 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 321 | 402 | 443 | 820 | 864 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −31.3x | −9.6x | −11.6x | −3.7x | −3.7x |
| Current ratio | — | 4.7x | 3.8x | 4.4x | 4.0x |
| Quick ratio | — | 4.7x | 3.8x | 4.4x | 4.0x |
Cash flow
Projections
Project Immunocore's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Immunocore shares on the open market, and 4 insiders sold $5.6 million, $5.0 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Feb 18, 2026 | Bahija JallalChief Executive Officer, Director | Sold | 11,474 | $32.35 | $371,184 | Form 4 |
| Feb 18, 2026 | David M BermanHead of R&D | Sold | 5,965 | $32.35 | $192,968 | Form 4 |
| Feb 18, 2026 | Leger Tina Amber StChief HR Officer | Sold | 1,000 | $32.35 | $32,350 | Form 4 |
| Feb 18, 2026 | John GollSVP, Finance & CAO | Sold | 698 | $32.35 | $22,580 | Form 4 |
| Dec 5, 2025 | David M BermanHead of R&D | Sold plan | 572 | $40.14 | $22,960 | Form 4 |
| Dec 4, 2025 | David M BermanHead of R&D | Sold plan | 31,341 | $40.26 | $1.3 million | Form 4 |
| Nov 28, 2025 | David M BermanHead of R&D | Sold plan | 5,521 | $40.09 | $221,337 | Form 4 |
| Nov 26, 2025 | David M BermanHead of R&D | Sold plan | 69,404 | $40.12 | $2.8 million | Form 4 |
| Nov 25, 2025 | David M BermanHead of R&D | Sold plan | 18,020 | $40.03 | $721,341 | Form 4 |
| Nov 24, 2025 | David M BermanHead of R&D | Sold plan | 100 | $40.00 | $4,000 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 42.1% | 31.1% | 25.2% |
| Altman Z'' | 1.24 | 2.21 | 2.37 |
| Accruals ratio | −10.4% | −9.6% | −2.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Fail |
| Return on assets rose | — | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | — | Pass | Fail |
| F-score | — | — | — |
Compare
Put Immunocore side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Immunocore | FY25 | 28.9% | −11.3% | −3.8% | — | — | — | |
| Krystal Biotech | FY25 | 33.9% | 41.5% | 48.5% | 43.6% | −5.0x | 5 | Compare |
| Arrowhead Pharmaceuticals | FY26 | −45.6% | −156.9% | −63.0% | — | — | 2 | Compare |
| Tarsus Pharmaceuticals | FY25 | 146.7% | −15.7% | −4.9% | — | — | 4 | Compare |
| Twist Bioscience | FY26 | 22.0% | −30.4% | −19.4% | — | — | — | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | 36 | 174 | 249 | 310 | 400 |
| Revenue growth | — | — | — | — | 377.9% | 43.0% | 24.4% | 28.9% |
| Gross profit | — | — | — | 36 | 173 | 248 | 308 | 395 |
| Research and development | — | — | — | 100 | 102 | 164 | 222 | 275 |
| Operating income | — | — | — | −175 | −52 | −60 | −70 | −45 |
| Net income | — | — | — | −180 | −52 | −55 | −51 | −36 |
| Diluted EPS (US$) | — | — | — | −4.24 | −1.15 | −1.13 | −1.02 | −0.71 |
| Diluted shares (millions) | 22 | 22 | 26 | 42 | 46 | 49 | 50 | 50 |
| Cash flow | ||||||||
| Cash from operations | — | — | — | −143 | −49 | 3 | 26 | −11 |
| Capital expenditure | — | — | — | 1 | 2 | 5 | 5 | 4 |
| Free cash flow | — | — | — | −144 | −51 | −2 | 21 | −15 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | — | — | 49 | 33 | 32 | 34 | 38 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | — | — | 177 | 321 | 402 | 443 | 820 | 864 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — |
| Total assets | — | — | — | — | 527 | 597 | 1,010 | 1,067 |
| Total liabilities | — | — | — | — | 188 | 228 | 649 | 686 |
| Shareholders' equity | — | — | 77 | 234 | 339 | 369 | 361 | 381 |
| Margins and ratios | ||||||||
| Gross margin | — | — | — | 100.0% | 99.4% | 99.6% | 99.1% | 98.7% |
| Operating margin | — | — | — | −478.5% | −29.7% | −23.9% | −22.7% | −11.3% |
| Net margin | — | — | — | −493.4% | −30.1% | −22.2% | −16.5% | −8.9% |
| Free cash flow margin | — | — | — | −396.0% | −29.5% | −1.0% | 6.7% | −3.8% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | 348.4% | 42.1% | 31.1% | 25.2% |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | — | — | — | — | −15.6% | −14.0% | −9.6% |
| Return on assets | — | — | — | — | — | −9.8% | −6.4% | −3.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |